Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

NCT ID NCT03630159
Title Study of Tisagenlecleucel in Combination With Pembrolizumab in r/r Diffuse Large B-cell Lymphoma Patients (PORTIA)
Recruitment Completed
Gender both
Phase Phase I
Variant Requirements No
Sponsors Novartis Pharmaceuticals
Indications

diffuse large B-cell lymphoma

Therapies

Pembrolizumab + Tisagenlecleucel

Age Groups: senior | adult
Covered Countries USA | CAN | AUT

Facility Status City State Zip Country Details
Emory University School of Medicine SC CTL019 Atlanta Georgia 30322 United States Details
University of Chicago Medical Center Hematology and Oncology Chicago Illinois 60637 United States Details
University of Kansas Hospital and Medical Center U of Kansas Cancer Center Kansas City Kansas 66160 United States Details
Novartis Investigative Site Wien 1090 Austria Details
Novartis Investigative Site Montreal Quebec H1T 2M4 Canada Details
*Shaded cells indicate that there was no data available from clincialtrials.gov for the field